Vimarsana
Biggest News Aggregation in the World

Junior Faculty News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Junior Faculty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Junior Faculty Today - Breaking & Trending Today

CNN CNN This Morning June 11, 2024 - Vimarsana News

CNN CNN This Morning June 11, 2024

her uncle's unhappy. i'm sensing an underlying issue. it's t-mobile. it started when we tried to get him under a new plan. but they they unexpectedly unraveled their “price lock” guarantee. which has made him, a bit... unruly. you called yourself the “un-carrier”. you sing about “price lock” on those commercials. “the price lock, the price lock...” so, if you could change the price, change the name! it's not a lock, i know a lock. so how can we undo the damage? we could all unsubscribe and switch to xfinity. their connection is unreal. and we could all un-experience t...

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer - Vimarsana News

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer - Vimarsana News

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer - Vimarsana News

Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer

Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Global Scientist Interdisciplinary Forum & Recruitment job with Southern University of Science and Technology, School of Medicine - Vimarsana News

Global Scientist Interdisciplinary Forum & Recruitment job with Southern University of Science and Technology, School of Medicine

Global Scientist Interdisciplinary Forum & Recruitment job in Shenzhen, Guangdong, China with Southern University of Science and Technology, School of Medicine. Apply Today.

Source: nature.com